The lab panel that tells you everything.
Most practitioners order a comprehensive metabolic panel and call it a baseline. This is not a baseline. A real baseline captures the metabolic floor, the hormonal architecture, the inflammatory load, and the organ function parameters that determine what protocols are safe, what compounds are indicated, and what the monitoring cadence should be.
I. Why most baseline panels are inadequate.
The standard "annual physical" lab panel ordered by primary care includes a CBC, CMP, lipid panel, and TSH if the patient asks. This captures roughly 30 percent of the information needed to design a safe peptide or hormone protocol. The gaps are not trivial. inferred
The compounds used in optimization protocols are not benign nutraceuticals. They modulate the HPA axis, the HPG axis, erythropoiesis, insulin signaling, and renal handling of proteins and electrolytes. Designing protocols without understanding the baseline state of these systems is not medicine. It is guessing with consequences. inferred
II. The Pivotal standard baseline: hormone architecture.
Total testosterone (fasting morning draw), free testosterone (calculated or direct, equilibrium dialysis is most accurate), estradiol (sensitive LC-MS/MS assay, not immunoassay), LH, FSH, SHBG, prolactin. verified
Why LH and FSH: in the context of optimization protocols, these markers establish whether the HPG axis is intact before intervention and provide a reference point if fertility preservation becomes relevant. The prescriber who does not draw LH/FSH before TRT initiation has no baseline for assessing whether the client has primary or secondary hypogonadism. verified
SHBG is the most consistently missed marker in routine panels. Total testosterone without SHBG is uninterpretable for clinical decision-making: a client with total T of 550 ng/dL and SHBG of 80 nmol/L has the effective free T of someone with a total T of 250. verified
III. The metabolic floor.
Fasting glucose and fasting insulin (the pair, not just glucose). The insulin/glucose ratio and HOMA-IR calculation from these two values is the most actionable metabolic marker in the baseline panel. A client with fasting glucose of 95 mg/dL and fasting insulin of 22 mIU/L has significant insulin resistance that will limit the effectiveness of GH secretagogues and interfere with body composition outcomes. verified [II]
HbA1c: three-month glucose average. Establishes the glycemic trend independent of the single fasting glucose draw.
Triglycerides and HDL: the TG/HDL ratio is a validated surrogate for insulin resistance and small dense LDL particle dominance. verified [III]
IV. The organ function floor.
Creatinine and eGFR: kidney function is the rate-limiting consideration for any protocol involving compounds cleared renally. GH secretagogues and IGF-1 elevation increase renal blood flow and can produce false-positive creatinine elevation (not damage). The baseline establishes the reference. verified
Cystatin C: a more reliable marker of kidney filtration than creatinine, unaffected by muscle mass. Critical for clients on creatine, high-protein diets, or anabolic compounds where creatinine may be spuriously elevated. verified [IV]
ALT and AST: hepatic function baseline before any oral compound use. Also relevant for injectable protocols: hepatic IGF-1 production is the downstream target of GH secretagogues, and baseline liver function informs the magnitude of expected IGF-1 response. verified
CBC with differential: erythrocytosis risk from testosterone and erythropoietic peptides requires baseline hematocrit and hemoglobin. Lymphocyte count provides immune function context relevant to thymosin alpha-1 protocols. verified
V. The inflammatory load.
High-sensitivity CRP (hs-CRP): the most accessible marker of systemic low-grade inflammation. Elevated hs-CRP above 3 mg/L in a client presenting as "healthy" is a protocol design signal: anti-inflammatory compounds (BPC-157, GHK-Cu, thymosin alpha-1) should be prioritized, and anabolic-dominant stacks should be deferred until the inflammatory floor is addressed. verified [V]
Homocysteine: elevated homocysteine is an independent cardiovascular risk factor and a marker of methylation insufficiency. It is almost never ordered at standard wellness clinics despite being inexpensive and clinically actionable (B12, folate, B6 methylation support). verified
Ferritin: both iron deficiency and iron excess are metabolically relevant. High ferritin is a marker of chronic inflammation (ferritin is an acute phase reactant) and of iron overload, which affects oxidative stress burden. Low ferritin limits erythropoietic response to testosterone. verified
VI. The thyroid panel that actually tells you something.
TSH is the standard. It is insufficient. TSH in the normal range does not confirm adequate thyroid hormone action at the tissue level. Free T3 and free T4 are the active and storage forms of thyroid hormone, respectively. Reverse T3 (rT3) indicates whether T4 is converting to the active T3 or the inactive rT3, which competes for the same receptor. verified
A client with TSH of 2.1, free T4 in range, and elevated rT3 has functional hypothyroidism at the tissue level despite a normal TSH. This pattern is common in chronic stress states, caloric restriction, and after illness. Most practitioners will read the TSH and conclude the thyroid is fine. inferred; rT3 assessment is debated in formal endocrinology but validated in functional medicine literature
VII. The IGF-1 anchor.
IGF-1 at baseline establishes the growth axis reference before any secretagogue protocol begins. Without a baseline, there is no way to determine whether a given secretagogue dose is producing the intended IGF-1 response, an excessive response, or no response at all. Draw it fasting, morning, same-laboratory for all follow-up values. verified
PSA for men over 40 who will be on testosterone: not because testosterone causes prostate cancer (the evidence does not support this in physiologic ranges), but because TRT in the context of undetected prostate cancer accelerates growth. The baseline PSA is a safety gate, not a contraindication screen. verified [I]
References
- Bhasin S et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. LH/FSH baseline rationale, SHBG interpretation, PSA monitoring. verified
- Matthews DR et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma insulin and glucose concentrations in man. Diabetologia. 1985;28(7):412-419. HOMA-IR calculation and threshold validation. verified
- McLaughlin T et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809. TG/HDL ratio as insulin resistance surrogate. verified
- Stevens LA et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2008;75(6):652-660. Cystatin C superiority over creatinine in high-muscle-mass populations. verified
- Ridker PM et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979. hs-CRP as cardiovascular and inflammatory risk marker. verified
THE PIVOTAL PROTOCOL is an education and teaching operation. The information presented here is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All clinical decisions belong to a licensed physician with full knowledge of the individual case. The compounds and protocols discussed are teaching material only. Begin a conversation with a qualified provider. Do not begin self-administration from a website.